Show simple item record

dc.contributor.authorSawan, S
dc.contributor.authorBurt, Deborah J
dc.contributor.authorStern, Peter L
dc.contributor.authorHolland, C
dc.contributor.authorElkord, Eyad
dc.date.accessioned2011-12-02T14:47:19Z
dc.date.available2011-12-02T14:47:19Z
dc.date.issued2011
dc.identifier.citationCirculating regulatory T cells in endometrial cancer: a role for age and menopausal status. 2011, 40 (1):62-75 Immunol Investen
dc.identifier.issn1532-4311
dc.identifier.pmid20809698
dc.identifier.doi10.3109/08820139.2010.513022
dc.identifier.urihttp://hdl.handle.net/10541/192869
dc.description.abstractRegulatory T cells (Treg) are a sub-population of T cells that suppress self-reactivity and are implicated in immune tolerance towards malignant cells. Circulating Treg cells are increased in several cancers. In endometrial cancer Treg cells have been investigated only in tumour tissues and, in contrast to some other tumours, fewer Treg cells were reported in endometrial cancer compared with benign controls. Flow cytometry was used to determine the frequency of circulating Treg cells in women undergoing hysterectomy for either endometrial cancer (n = 24) or non- cancer-related conditions (n = 21). Circulating Treg cells were more abundant in women with cancer compared to those without (4.68% vs. 3.66%, p = 0.05, Mann-Whitney test). This relationship disappeared, however, when only data from post-menopausal women were included in the analysis. Mean Treg cell frequency was 4.65% in postmenopausal women with cancer (n = 23) and 4.73% in postmenopausal controls (n = 5) (p = 0.9). In women without cancer we found that mean Treg cell frequency was higher in postmenopausal women (4.73%, n = 5) in comparison to premenopausal controls (3.33%, n = 16) (p = 0.02). These results suggest that the increased proportion of Treg cells seen in endometrial cancer patients might be, at least in part, attributed to their postmenopausal status or age.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAging
dc.subject.meshAntigens, CD4
dc.subject.meshEndometrial Neoplasms
dc.subject.meshFemale
dc.subject.meshFlow Cytometry
dc.subject.meshForkhead Transcription Factors
dc.subject.meshHumans
dc.subject.meshHysterectomy
dc.subject.meshLymphocyte Count
dc.subject.meshMenopause
dc.subject.meshMiddle Aged
dc.subject.meshPostmenopause
dc.subject.meshPremenopause
dc.subject.meshT-Lymphocytes, Regulatory
dc.titleCirculating regulatory T cells in endometrial cancer: a role for age and menopausal status.en
dc.typeArticleen
dc.contributor.departmentAcademic Unit of Obstetrics and Gynaecology, School of Cancer and Enabling Sciences, The University of Manchester, Manchester, United Kingdom. saladin.sawan@manchester.ac.uken
dc.identifier.journalImmunological Investigationsen
html.description.abstractRegulatory T cells (Treg) are a sub-population of T cells that suppress self-reactivity and are implicated in immune tolerance towards malignant cells. Circulating Treg cells are increased in several cancers. In endometrial cancer Treg cells have been investigated only in tumour tissues and, in contrast to some other tumours, fewer Treg cells were reported in endometrial cancer compared with benign controls. Flow cytometry was used to determine the frequency of circulating Treg cells in women undergoing hysterectomy for either endometrial cancer (n = 24) or non- cancer-related conditions (n = 21). Circulating Treg cells were more abundant in women with cancer compared to those without (4.68% vs. 3.66%, p = 0.05, Mann-Whitney test). This relationship disappeared, however, when only data from post-menopausal women were included in the analysis. Mean Treg cell frequency was 4.65% in postmenopausal women with cancer (n = 23) and 4.73% in postmenopausal controls (n = 5) (p = 0.9). In women without cancer we found that mean Treg cell frequency was higher in postmenopausal women (4.73%, n = 5) in comparison to premenopausal controls (3.33%, n = 16) (p = 0.02). These results suggest that the increased proportion of Treg cells seen in endometrial cancer patients might be, at least in part, attributed to their postmenopausal status or age.


This item appears in the following Collection(s)

Show simple item record